Navigation Links
Novartis files application with FDA for Zometa

Novartis Pharmaceuticals has submitted an application to the Food and Drug Administration, seeking marketing authorization for Zometa in the treatment of bone complications associated with a broad range of tumor types. These include prostate and lung cancer, for which no bisphosphonate therapy is currently approved. The spread of cancerous cells from the original tumor to the bone, can lead to serious complications called skeletal related events like fractures, compression of the spinal cord, severe bone pain and hypercalcemia.//

Zometa is a new generation intravenous bisphosphonate that was approved by the FDA just two weeks ago (20 August 2001) for the treatment of hypercalcemia of malignancy (HCM), the most common life-threatening metabolic complication of cancer. To date, Novartis has received marketing clearances for Zometa in the treatment of hypercalcemia of malignancy (HCM) in more than 30 countries.

"Bone complications can be extremely debilitating to cancer patients, and seriously impact their day to day activities. Zometa offers these patients an effective treatment with a convenient 15-minute infusion time. Novartis is pleased to bring forward another drug that will help make a marked difference in the lives of cancer patients and their families" said David Epstein, President, Novartis Oncology.

Three trials have been successfully conducted, evaluating more than 3,000 patients. This is the largest set of clinical trials ever conducted to evaluate the efficacy and tolerability of bisphosphonates in treating bone complications.


'"/>




Page: 1

Related medicine news :

1. Canine Painkiller unveiled by Novartis
2. Glivec the hot cancer drug from Novartis
3. Zometa [Novartis Drug] For Treatment Of Paget’s Diseas
4. Novartis MS Drug Shows Promising Results
5. Bird-flu Vaccine Adjuvant Contract Goes to Novartis
6. Drop Patent Petition, Activists Ask Novartis
7. E.U. Panel Backs Novartis Mock-up Pandemic Flu Vaccine
8. Indian Court Refers Novartis Plea for Patent on Anti-cancer Drug to a Separate Board
9. Novartis Gleevec Found Effective in Treating Gastro-intestinal Tumors
10. Novartis Drug Diovan Shows Superior Benefits
11. Unfavourable Lipid-Lipoprotein profiles in older adults has been linked to abdominal visceral fat

Post Your Comments:
(Date:11/30/2009)...ov. 30 EMD Serono, an affiliate of...hat it received a refuse to file letter from the U...ug Application (NDA) for Cladribine Tablets, EMD S...on of cladribine, as a therapy for relapsing forms...ill work closely with the FDA to fully understand ...
(Date:11/30/2009)... still end up being swallowed, study finds , ... beverage cans -- the kind that stay attached once...n, who can swallow the tabs and damage their diges...hree decades ago, beverage makers starting using w...h were believed to pose a swallowing hazard for ch...
(Date:11/30/2009)...PC has released an online service that lets users ...his is the first hosted service in the world that ...am. Result, blazing fast performance even over slo...Clara, CA (PRWEB) November 30, 2009 -- ShowMyPC ha...Service that uses the familiar Microsoft Remote De...
(Date:11/30/2009)...ses Staten Island courtroom to recreate scene of a...responsible for client’s accident. , ...30, 2009 -- A Staten Island, N.Y. jury awarded a v... who was injured at a New York City construction s...n Construction Company et al (Index No. 102557/05,...
(Date:11/30/2009)...o, November 30 Simbionix USA Corpo...imulation systems, in collaboration,with GORE Medi...l Studio(TM),workshop for the first time at the up... The Simbionix PROcedure Rehearsal Studio(TM) i...inicians to create practice scenarios based on the...
Breaking Medicine News(10 mins):Health News:EMD Serono Receives Refuse to File Letter from FDA on Cladribine Tablets New Drug Application 2Health News:EMD Serono Receives Refuse to File Letter from FDA on Cladribine Tablets New Drug Application 3Health News:Beverage Can Tabs Remain a Risk for Kids 2Health News:ShowMyPC Provides First Online Service in the World to Access Personal Computers from Anywhere Using Microsoft Remote Desktop 2Health News:Raphaelson & Levine Secures $1.1 Million Verdict for Victim of New York Construction Accident 2Health News:Simbionix First Procedure Rehearsal Studio(TM) Training Workshop 2Health News:Simbionix First Procedure Rehearsal Studio(TM) Training Workshop 3
...nounced today new compact,ProSound ultrasound Syst...,European Federation of Societies for Ultrasound i...2008, in Timisoara, Romania. The ProSound 2 is a,p...e premium models of the ProSound series are incorp...
...Orphan Therapeutics today,announced that it has be...essin) New Drug Application (NDA) for the treatmen... with late-stage liver cirrhosis.,LUCASSIN(R) had ... is approved in the U.S. to treat HRS type 1, a,ra...
...uthor and psychologist Dr. Jed,Baker will discuss ...rders,during a conference co-sponsored by the Penn...h of a series of eight conferences by distinguishe...ombetta, CEO of the Pennsylvania Cyber Charter Sch...
... - Preliminary Proxy Results,...Corporation (NYSE: LDG ) today announced a cash d...008 Annual Meeting of Stockholders., The Board of...rs of record at the close of business on June 3,20...
...m Effects of $35 Cost Per Metric Ton of CO2 ...sible, PITTSBURGH, May 28 As recent judicial, po...ue to move the United States toward a,mandatory pr...-term effects of establishing such a cost. The res...
...N.V. (NYSE: HOO ) ("the,Company"), a leading prov...ntries, today announced that it plans to present a...ference at the Sheraton New York Hotel &,Towers in...ss and financial highlights, and will be available...
Other Medicine News:Health News:ALOKA to Unveil a New Compact 'ProSound' Diagnostic Ultrasound System 2Health News:Orphan Therapeutics Announces Initiation of Rolling NDA Submission for LUCASSIN(R) (terlipressin) for the Treatment of Hepatorenal Syndrome Type 1 2Health News:Orphan Therapeutics Announces Initiation of Rolling NDA Submission for LUCASSIN(R) (terlipressin) for the Treatment of Hepatorenal Syndrome Type 1 3Health News:Autism Author and Psychologist Dr. Jed Baker to Speak on Communication Disorders 2Health News:Longs Drug Stores Corporation Announced at Its Annual Meeting of Stockholders 2Health News:Establishing a Price for Carbon Emissions in the U.S. Would Spur Immediate Reductions in Energy Consumption and More Efficient Use of Power Generators, Study by Carnegie Mellon Researchers Shows 2Health News:Establishing a Price for Carbon Emissions in the U.S. Would Spur Immediate Reductions in Energy Consumption and More Efficient Use of Power Generators, Study by Carnegie Mellon Researchers Shows 3
(Date:11/29/2009)...GO, Nov. 30 Elastography is an eff...reast ultrasound, helps distinguish cancerous brea...going study presented today at the annual meeting ...). ,, When mammography yields suspicious findin...tional information. However, ultrasound has the po...
(Date:11/29/2009)...HICAGO, Nov. 29 Royal Philips Elec...nse to an industry need by showing its portfolio o...is year,s 95th annual meeting of the Radiological ...his year from Philips are several advancements and...dose radiation and streamlining workflow to expand...
(Date:11/29/2009)...GO, Nov. 29 Stimulated by the ten ...Fujifilm Medical Systems USA announced today, at t...nual meeting, the formation of its Medical Inform...ms, this new group will integrate all functions as...nd creates a platform for future growth. ,, Sev...
Breaking Medicine Technology:Elastography Reduces Unnecessary Breast Biopsies 2Elastography Reduces Unnecessary Breast Biopsies 3Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients 2Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients 3Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients 4Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients 5FUJIFILM Establishes Medical Informatics Organization 2FUJIFILM Establishes Medical Informatics Organization 3Robert Brady 28D PA 1 29 Chaka Fattah 28D PA 2 29 Kathy Dahlkemper 28D PA 3 29 Joe Sestak 28D PA 7 29 Patrick Murphy 28D PA 8 29 Christopher 60908 1Robert Brady 28D PA 1 29 Chaka Fattah 28D PA 2 29 Kathy Dahlkemper 28D PA 3 29 Joe Sestak 28D PA 7 29 Patrick Murphy 28D PA 8 29 Christopher 60908 2Hollywood Stars Joined in a Celebration of Babies 60906 1Hollywood Stars Joined in a Celebration of Babies 60906 2Hollywood Stars Joined in a Celebration of Babies 60906 3Indiana U at APHA 3A Studies about health education for people with ID stability balls at work 10651 1Indiana U at APHA 3A Studies about health education for people with ID stability balls at work 10651 2Indiana U at APHA 3A Studies about health education for people with ID stability balls at work 10651 3
...RNewswire/ -- DNA Therapeutics,S.A. an emerging ph...cer therapy announces today the elucidation of a n... biomarker of its,first-in-class antitumoral lead ...ming American Association for Cancer,Research annu...ine.,The presentation itself will be available fro...
...ented on Valopicitabine Combined,with an Investiga... 12, 2007 /PRNewswire-FirstCall/ --,Idenix Pharmac...ase,IIb studies of the novel combination of valopi...(Pegasys(R)) in both treatment-naive,and treatment...1,strain of the hepatitis C virus (HCV). These dat...
Other Medicine Technology:DNA Therapeutics Reports a Novel Mechanism of Action and a,Biomarker of its Lead Molecule Dbait That Open an Innovative,Pathway-Targeting in Molecular Cancer Therapy 2DNA Therapeutics Reports a Novel Mechanism of Action and a,Biomarker of its Lead Molecule Dbait That Open an Innovative,Pathway-Targeting in Molecular Cancer Therapy 3Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 2Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 3Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 4Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 5Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 6Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 7
Lieberman Wire Angled Speculum
Needle Holder (Without Lock)
Chopper / Manipulator
Capsule polisher
Medicine Products: